AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Pharma company reports second quarter 2004 results.
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Point Therapeutics, Inc., (NASDAQ: POTP) reported results for the fiscal quarter and 6 months ended June 30, 2004.
During the second quarter of 2004, Point achieved the following key milestones:
- Initiated three Phase 2 talabostat (PT-100) human clinicalstudies in: advanced metastatic melanoma patients studying talabostat as a single agent, advanced metastatic melanoma patients combining talabostat with cisplatin, advanced chronic lymphocytic leukemia patients combining talabostat with rituximab
- Initiated trading of Point's Common Stock on the NASDAQ Small Cap Market on April 2, 2004
- Presented Phase 1 clinical data at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2004
- Announced the appointment of a clinical advisory board to assist Point in developing its clinical and scientific strategy
- Appointed two new members to the board of directors: Larry G.Pickering, global chairman CSFB Private Equity and former Johnson & Johnson senior executive; Dr. Richard Benjamin, chief medical officer of the American Red Cross, New England Region, and assistant professor of Pathology at Harvard Medical School
- Poxvirus used for delivery of stimulatory molecules to melanoma tumors.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Delivery, Skin Cancer, Dermatology, Immunotherapy, Vaccine Development, and Oncology. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Broadly cross-reactive HIV-neutralizing antibody Fab identified.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Therapy, Vaccine Development, Monoclonal Antibodies, Diagnostics, and Immunotherapy. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Arginine-glysine-aspartate motif enhances immunogenicity of antigens.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Delivery, Vaccine Development, Vaccine Efficacy, Immunology, and Immunotherapy. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Cancer vaccine using low affinity epitopes proves successful in mice.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...This article may be viewed at https://www.the-jci.org/press/19418.pdf. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- DNA induces T helper type 1-mediated responses in antigen-primed mice.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Bacteriology, Biological Therapy, Immunology, Immunotherapy, Oncology, and Proteomics. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Researcher reviews novel cancer vaccines.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Vaccine Development, Vaccine Efficacy, Immunotherapy, Proteomics, and Oncology. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Call for increase in flu vaccination among young children.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...administration should make it possible to increase the use of influenza vaccination." This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Positive results of cholera vaccine trial in Bangladesh reported.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...vaccines against anthrax or other organisms that might be used as biowarfare agents. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Typhoid/hepatitis A vaccine effective as booster dose in primed adults.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Vaccine Efficacy, Vaccine Development, Hepatitis A Virus, Virology, and Hepatology. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Lock to food-borne pathogen pathway may be key to vaccine.
- Newspaper article from: Vaccine Weekly February 18, 2004 700+ words
...Medicine and the U.S. Department of Agriculture-Agricultural Research Service. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
Source: HighBeam Research, Pharma company reports second quarter 2004 results.